Athira Pharma has dosed the first patient in its Phase 2 clinical trial evaluating ATH-1017 as a treatment for Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) — forms of more severe cognitive impairment in Parkinson’s disease. The trial (NCT04831281), known as SHAPE, is still recruiting patients, ages 40-85, at five different locations across the United […]

The U.S. Food and Drug Administration (FDA) has given positive feedback to Annovis Bio’s plans to start two Phase 3 clinical trials of buntanetap (ANVS401) as an oral therapy for early- and late-stage Parkinson’s disease. The feedback followed a review of data from a Phase 2 clinical trial showing significant gains in motor skills among early Parkinson’s patients treated once […]

A phase 1/2a clinical trial of the first allogeneic RNA cell therapy in multiple myeloma has begun after dosing its first patient this week. The trial aims to examine the treatment — Descartes-25 — in 20 patients with relapsed/refractory multiple myeloma. “Patients with relapsed and/or refractory multiple myeloma have few treatment options remaining,” said Dr. […]